| Symbol | DYN |
|---|---|
| Name | DYNE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1560 TRAPELO ROAD, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 781 786-8230 |
| Fax | — |
| — | |
| Website | https://www.dyne-tx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001818794 |
| Description | Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. Additional info from NASDAQ: |
(30% Negative) DYNE THERAPEUTICS, INC. (DYN) Reports Q3 2026 Financial Results
Read moreDyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Read moreDyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Read moreDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreDyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Read moreNew Form 424B5 - Dyne Therapeutics, Inc. <b>Filed:</b> 2026-07-22 <b>AccNo:</b> 0001193125-26-312576 <b>Size:</b> 678 KB
Read moreDyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Read moreNew Form 424B5 - Dyne Therapeutics, Inc. <b>Filed:</b> 2026-07-21 <b>AccNo:</b> 0001193125-26-310573 <b>Size:</b> 534 KB
Read more